Edward Loftus Jr., M. D., discusses the recent Food and Drug Administration approval of a new treatment for ulcerative colitis. Dr. Loftus explains the process Uceris, a budesonide foam, went through to receive FDA approval. The phase three trials found higher remission rates, improvement in disease activity, and rectal bleeding.
The new drug will be available soon for treatment of ulcerative colitis.
For more information about IBD, visit mayoclinic.org/IBD.
Dr. Loftus is a gastroenterologist at Mayo Clinic.